Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome

Detalles Bibliográficos
Autores principales: Schmidt, Tilman, Gödel, Markus, Mahmud, Maida, Fischer, Lutz, Huber, Tobias B., Kluger, Malte A., Grahammer, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806379/
https://www.ncbi.nlm.nih.gov/pubmed/35187213
http://dx.doi.org/10.1097/TXD.0000000000001289
_version_ 1784643429961039872
author Schmidt, Tilman
Gödel, Markus
Mahmud, Maida
Fischer, Lutz
Huber, Tobias B.
Kluger, Malte A.
Grahammer, Florian
author_facet Schmidt, Tilman
Gödel, Markus
Mahmud, Maida
Fischer, Lutz
Huber, Tobias B.
Kluger, Malte A.
Grahammer, Florian
author_sort Schmidt, Tilman
collection PubMed
description
format Online
Article
Text
id pubmed-8806379
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-88063792022-02-18 Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome Schmidt, Tilman Gödel, Markus Mahmud, Maida Fischer, Lutz Huber, Tobias B. Kluger, Malte A. Grahammer, Florian Transplant Direct Letter to the Editor Lippincott Williams & Wilkins 2022-01-26 /pmc/articles/PMC8806379/ /pubmed/35187213 http://dx.doi.org/10.1097/TXD.0000000000001289 Text en Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Letter to the Editor
Schmidt, Tilman
Gödel, Markus
Mahmud, Maida
Fischer, Lutz
Huber, Tobias B.
Kluger, Malte A.
Grahammer, Florian
Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
title Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
title_full Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
title_fullStr Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
title_full_unstemmed Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
title_short Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
title_sort ravulizumab in preemptive living donor kidney transplantation in hereditary atypical hemolytic uremic syndrome
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806379/
https://www.ncbi.nlm.nih.gov/pubmed/35187213
http://dx.doi.org/10.1097/TXD.0000000000001289
work_keys_str_mv AT schmidttilman ravulizumabinpreemptivelivingdonorkidneytransplantationinhereditaryatypicalhemolyticuremicsyndrome
AT godelmarkus ravulizumabinpreemptivelivingdonorkidneytransplantationinhereditaryatypicalhemolyticuremicsyndrome
AT mahmudmaida ravulizumabinpreemptivelivingdonorkidneytransplantationinhereditaryatypicalhemolyticuremicsyndrome
AT fischerlutz ravulizumabinpreemptivelivingdonorkidneytransplantationinhereditaryatypicalhemolyticuremicsyndrome
AT hubertobiasb ravulizumabinpreemptivelivingdonorkidneytransplantationinhereditaryatypicalhemolyticuremicsyndrome
AT klugermaltea ravulizumabinpreemptivelivingdonorkidneytransplantationinhereditaryatypicalhemolyticuremicsyndrome
AT grahammerflorian ravulizumabinpreemptivelivingdonorkidneytransplantationinhereditaryatypicalhemolyticuremicsyndrome

Ejemplares similares